A Phase I Open-label Dose Escalation Study of Once-daily Oral Treatment With BIBF 2992 for 21 Days in Patients With Advanced Solid Tumors
收藏Mendeley Data2024-01-31 更新2024-06-27 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003683/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective was the assessment of safety of BIBW 2992 as assessed by the maximum tolerated dose (MTD). Secondary objectives were collection of overall safety data, antitumor efficacy data, as well as the determination of pharmacokinetics and the pharmacodynamic modulation of biomarkers by BIBW 2992.
创建时间：
2024-01-31
